Abstract
Purpose To evaluate vitrectomy with subretinal tissue plasminogen activator (t-PA) injection, and air tamponade, followed by intravitreal anti-vascular endothelial growth factor (VEGF) therapy for submacular hemorrhage in polypoidal choroidal vasculopathy (PCV). Design Prospective, interventional case series. Methods setting: Two clinics. patients: Fifteen eyes of 15 consecutive patients (mean age 72 ± 7 years) with submacular hemorrhage attributable to PCV. inclusion criteria: PCV diagnosis with unorganized submacular hemorrhage greater than 500 μm thick. exclusion criteria: Submacular hemorrhage attributable to macular diseases (eg, high myopia, typical age-related macular degeneration, retinal angiomatous proliferation, and angioid streaks). intervention: Vitrectomy with 4000 IU t-PA injected subretinally and fluid/air exchange. Patients remained facedown for 3 days after surgery. Anti-VEGF drugs were administered as exudative changes required. main outcome measures: Submacular hemorrhage displacement from the macula and changes in best-corrected visual acuities (BCVAs). Results Mean time from onset to surgery was 9.5 ± 4.5 (range, 5-21) days. Mean follow-up period was 9.4 ± 3.1 (range, 6-17) months. Surgery successfully displaced submacular hemorrhages from the macula in all eyes. Mean BCVA at baseline (0.98 ± 0.44) had improved significantly both 1 month after surgery (0.41 ± 0.25, P
| Original language | English |
|---|---|
| Pages (from-to) | 683-689 |
| Number of pages | 7 |
| Journal | American Journal of Ophthalmology |
| Volume | 159 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 1 2015 |
Fingerprint
ASJC Scopus subject areas
- Ophthalmology
- Medicine(all)
Cite this
Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator. / Kimura, Shuhei; Morizane, Yuki; Hosokawa, Mio; Shiode, Yusuke; Kawata, Tetsuhiro; Doi, Shinichiro; Matoba, Ryo; Hosogi, Mika; Fujiwara, Atsushi; Inoue, Yasushi; Shiraga, Fumio.
In: American Journal of Ophthalmology, Vol. 159, No. 4, 01.04.2015, p. 683-689.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator
AU - Kimura, Shuhei
AU - Morizane, Yuki
AU - Hosokawa, Mio
AU - Shiode, Yusuke
AU - Kawata, Tetsuhiro
AU - Doi, Shinichiro
AU - Matoba, Ryo
AU - Hosogi, Mika
AU - Fujiwara, Atsushi
AU - Inoue, Yasushi
AU - Shiraga, Fumio
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Purpose To evaluate vitrectomy with subretinal tissue plasminogen activator (t-PA) injection, and air tamponade, followed by intravitreal anti-vascular endothelial growth factor (VEGF) therapy for submacular hemorrhage in polypoidal choroidal vasculopathy (PCV). Design Prospective, interventional case series. Methods setting: Two clinics. patients: Fifteen eyes of 15 consecutive patients (mean age 72 ± 7 years) with submacular hemorrhage attributable to PCV. inclusion criteria: PCV diagnosis with unorganized submacular hemorrhage greater than 500 μm thick. exclusion criteria: Submacular hemorrhage attributable to macular diseases (eg, high myopia, typical age-related macular degeneration, retinal angiomatous proliferation, and angioid streaks). intervention: Vitrectomy with 4000 IU t-PA injected subretinally and fluid/air exchange. Patients remained facedown for 3 days after surgery. Anti-VEGF drugs were administered as exudative changes required. main outcome measures: Submacular hemorrhage displacement from the macula and changes in best-corrected visual acuities (BCVAs). Results Mean time from onset to surgery was 9.5 ± 4.5 (range, 5-21) days. Mean follow-up period was 9.4 ± 3.1 (range, 6-17) months. Surgery successfully displaced submacular hemorrhages from the macula in all eyes. Mean BCVA at baseline (0.98 ± 0.44) had improved significantly both 1 month after surgery (0.41 ± 0.25, P
AB - Purpose To evaluate vitrectomy with subretinal tissue plasminogen activator (t-PA) injection, and air tamponade, followed by intravitreal anti-vascular endothelial growth factor (VEGF) therapy for submacular hemorrhage in polypoidal choroidal vasculopathy (PCV). Design Prospective, interventional case series. Methods setting: Two clinics. patients: Fifteen eyes of 15 consecutive patients (mean age 72 ± 7 years) with submacular hemorrhage attributable to PCV. inclusion criteria: PCV diagnosis with unorganized submacular hemorrhage greater than 500 μm thick. exclusion criteria: Submacular hemorrhage attributable to macular diseases (eg, high myopia, typical age-related macular degeneration, retinal angiomatous proliferation, and angioid streaks). intervention: Vitrectomy with 4000 IU t-PA injected subretinally and fluid/air exchange. Patients remained facedown for 3 days after surgery. Anti-VEGF drugs were administered as exudative changes required. main outcome measures: Submacular hemorrhage displacement from the macula and changes in best-corrected visual acuities (BCVAs). Results Mean time from onset to surgery was 9.5 ± 4.5 (range, 5-21) days. Mean follow-up period was 9.4 ± 3.1 (range, 6-17) months. Surgery successfully displaced submacular hemorrhages from the macula in all eyes. Mean BCVA at baseline (0.98 ± 0.44) had improved significantly both 1 month after surgery (0.41 ± 0.25, P
UR - http://www.scopus.com/inward/record.url?scp=84924858823&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924858823&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2014.12.020
DO - 10.1016/j.ajo.2014.12.020
M3 - Article
C2 - 25555798
AN - SCOPUS:84924858823
VL - 159
SP - 683
EP - 689
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
SN - 0002-9394
IS - 4
ER -